A Phase II Study of Iressa in Patients With Chemo Refractory Germ Cell Tumors Expressing EGFR

Inclusion Criteria: * Histologic or serologic proof of metastatic germ cell neoplasm(gonadal or extragonadal primary) with disease not amenable to cure with either surgery or chemotherapy. Patients w/ seminoma and non-seminoma are eligible, as are women w/ ovarian germ cell tumors. * Evidence of recurrent or metastatic carcinoma * Must have received initial cisplatin combination therapy \& demonstrated progression following the administration of at least one "salvage" regimen for advanced germ cell neoplasms. * Patients are eligible after first line platinum bsed chemotherapy if their disease has relapsed and they have primary mediastinal non seminomatous germ cell tumor, late relapse or progressed w/in 4 wks of last platinum dose. * immunohistochemical documentation of EGFR expression documented. * adequate organ function: ANC \>/=150,plt \>100K, total bili \</= upper limit of normal(ULN). Pts w/ liver mets up to 3x ULN.Transaminases up to 1.5 x ULN if alk phos is \</=ULN or alk phos may be up to 4x ULN if transaminases are \</= ULN. Pts w/ liver mets may have alk phos up to 5x ULN. Serum crt \</= 2.0. * ECOG performance status 0-2. Exclusion Criteria: * Must be 3 weeks post major surgery, radiotherapy, or chemotherapy and hae recovered from all toxicity. * Active unresolved infection and/or are receiving concurrent treatment with parenteral antibiotics are ineligible. * Patients requiring steroids for symptomatic brain metastasis are not eligible. * Pregnant or lactating patients are not eligible. * Class III/IV heart disease